Skip to main content

Patient receives first infusion of Biogen's controversial Alzheimer's drug

A 70-year-old man from Rhode Island on Wednesday was the first to receive an infusion outside of a clinical trial of Biogen's Alzheimer's drug, Aduhelm.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.